RNN - 16+ billion dollar market with THREE "BLOCKBUSTER" drugs in phase 2!...
Goldman Smallcap Research target $4.00 this year: some people even suggest $20.00 may be possible this year.
Three blockbuster drugs in development already passing phase 2 trials, all three of them. It's over three time bigger than DNDN.
I believe RNN will announce a significant partnership agreement(s) with a major pharma(s) starting 2Q '10. The management is excited about this. What RNN has in the pipeline is just too tempting to pass up for sevarl big pharms who have drugs coming off patent. Let's hope the boys at RNN are as good at negotiating as they are with the sciences. Teva Pharmaceuticals has already partnered with RNN to develop and commercialize the cancer compound RX-3117, which will bring milestone payments of millions of dollars mid-2010.. I do like the agreement with Teva- especailly the part where they agreed to buy shares at 20% higher than market. Tells me RNN has strong believers in important places.
The next catalyst comes from "Zoraxel" in a few weeks.
Here is the excerpt from an article:
"The company seems to have some big potential drugs in the pipeline. The one I like most if the Zoraxel. This drug could save a lot of marriages and could change the world if it has the same effect in humans as in rats. Its reported that Zoraxel creates/enhances the desire to have sex. The spanish fly if you will. We are talking way bigger than Cialis, and Viagra as they don't increase desire to have sex. So we are talking multi Billion dollar potential. The company has a current market cap of about 80 million at $1.22 a share.
They are 'at the same time' working on a drug for Zoraxel (Depression) and Archexin (Alzheimers)..'all best-in-class blockbusters'--11 billion dollar market and 'all already in phase 2 trials."
Comparing RNN with DNDN;
DNDN - 115 million O/S RNN's 71.9 million O/S
DNDN - 6.5% held by insiders RNN's - 33% held by insiders (it is estimated that 40%+ is tightly held by several Korean Corporations)
DNDN - 57.5% held by institutions RNN - 3.3% held by institutions
DNDN - float 113 million shares RNN - float 43 million shares, (as per Yahoo) - (it is estimated that the float is actually much smaller based on combined ownership of shares by Dr. Ahu's family and Korean Corporations - which would estimate a 10-15 million actual shares in the float )
Again, Goldman Smallcap Research target $4.00 this year--some people even suggest $20.00 may be possible this year. Three blockbuster drugs in development already passing phase 2 trials, all three of them. It's over three time bigger than DNDN, total 18+ billion dollar market.
Rexahn Pharmaceuticals on cusp of deal with big pharma company:
Market Data 
Markets 
AI
